EFFICACY AND SAFETY OF ANGIOTENSIN RECEPTOR BLOCKERS IN STAGE 1 HYPERTENSION: A HOSPITAL-BASED OBSERVATIONAL STUDY
DOI:
https://doi.org/10.22159/ajpcr.2025v18i7.54944Keywords:
Angiotensin receptor blockers, Hypertension, Losartan, Telmisartan, Olmesartan, Blood pressure, Joint National Committee 8, Efficacy, Safety, Stage 1 hypertensionAbstract
Objectives: This study aimed to evaluate the efficacy, safety, and tolerability of three commonly used angiotensin receptor blockers (ARBs)-losartan, telmisartan, and olmesartan-in managing stage 1 hypertension among patients aged 40–60 years.
Methods: A prospective observational study was conducted at a tertiary care hospital from March 2023 to March 2024. A total of 100 patients with stage 1 hypertension, as per joint national committee 8 criteria, were enrolled. Patients were randomly assigned to receive losartan (50–100 mg), telmisartan (40–80 mg), or olmesartan (20–40 mg) as monotherapy. Blood pressure, biochemical parameters, and adverse effects were monitored at baseline and at 15-day intervals for 3 months. Patients with secondary hypertension or compelling indications for other antihypertensive classes were excluded from the study.
Results: All three ARBs effectively reduced systolic and diastolic blood pressure (DBP). At 3 months, Olmesartan showed the highest mean reduction (systolic blood pressure: 30 mmHg, diastolic blood pressure: 16 mmHg), followed by telmisartan (26/12 mmHg) and losartan (20/12 mmHg). There were no significant changes in lipid profiles, renal function, or serum electrolytes. Only one patient experienced a mild headache with olmesartan. No serious adverse events occurred, and compliance was 100% throughout the study period.
Conclusion: ARBs are effective and well-tolerated in the treatment of stage 1 hypertension. Olmesartan demonstrated superior blood pressure control compared to losartan and telmisartan, without significant impact on biochemical parameters, highlighting its potential as a preferred monotherapy option.
Downloads
References
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth joint national committee (JNC 8). JAMA. 2014;311(5):507-20. doi: 10.1001/jama.2013.284427, PMID 24352797
World Health Organization. Hypertension. Geneva: World Health Organization; 2021. Available from: https://www.who.int/news-room/ fact-sheets/detail/hypertension [Last accessed on 2025 May 08].
Chiang CE, Wang TD, Li YH, Lin TH, Chien KL, Yeh HI, et al. 2010 Guidelines of the Taiwan society of cardiology for the management of hypertension. J Formos Med Assoc. 2010 Oct;109(10):740-73. doi: 10.1016/S0929-6646(10)60120-9, PMID 20970072
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/ APHA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13-5. doi: 10.1161/HYP.0000000000000065, PMID 29133356
Chaturvedi S, Lipszyc DH, Licht C, Craig JC, Parekh R. Pharmacological interventions for hypertension in children. Evid Based Child Health. 2014 Sep;9(3):498-580. doi: 10.1002/ebch.1974, PMID 25236305
Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman’s the Pharmacological Basis of Therapeutics Renin and Angiotensin. 11th ed. New York: McGraw-Hill; 2006. p. 789-821.
Giles TD, Oparil S, Silfani TN, Wang A, Walker JF. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich). 2007;9(3):187-95. doi: 10.1111/j.1524- 6175.2007.06395.x
Lacourcière Y, Krzesinski JM, White WB, Davidai G, Schumacher H. Sustained antihypertensive activity of telmisartan compared with valsartan. Blood Press Monit. 2004;9(4):203-10. doi: 10.1097/00126097-200408000-00005, PMID 15311147
Waeber B, Brunner HR. Losartan and the future of angiotensin II receptor antagonists. Am J Hypertens. 1995;8(12 Pt. 2):104S-8S. doi: 10.1016/0895-7061(95)00200-X
Fasce CF, Wagemann E. Antihypertensive efficacy and tolerability of losartan in patients with essential hypertension. Hypertension. 1999;33(1):178-82.
Cheung TT, Cheung BM. Managing blood pressure control in Asian patients: Safety and efficacy of losartan. Clin Interv Aging. 2014 Mar 19;9:443-50. doi: 10.2147/CIA.S39780, PMID 24672231
White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period. Am J Hypertens. 2004 Apr;17(4):347-53. doi: 10.1016/j.amjhyper.2004.02.016, PMID 15062889
Nishimura H, Inada T, Tominaga M. Efficacy and safety of telmisartan in Japanese patients with mild to moderate hypertension. Hypertens Res. 2002;25(3):405-10.
Ram CV. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: A review of factorial-design studies. Curr Med Res Opin. 2009 Jan;25(1):177-85. doi: 10.1185/03007990802597456, PMID 19210150
Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and hydrochlorothiazide provides additive antihypertensive efficacy and is well tolerated. J Clin Hypertens (Greenwich). 2004;6(3):138-46.
Neutel JM, Smith DH. A comparison of efficacy and tolerability of the angiotensin II receptor blocker telmisartan with enalapril. J Hum Hypertens. 2003;17(6):433-5.
Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90-8. doi: 10.1016/j.jash.2010.03.001
Koulouris S, Tsimihodimos V, Dounousi E, et al. The impact of antihypertensive treatment with angiotensin receptor blockers on inflammatory and oxidative stress markers in type 2 diabetic patients with albuminuria. Am J Hypertens. 2006;19(3):261-7. doi: 10.1016/j. amjhyper.2005.08.019
Lezama-Martinez D, Flores-Monroy J, Fonseca-Coronado S, Hernandez- Campos ME, Valencia-Hernandez I, Martinez-Aguilar L. Combined antihypertensive therapies that increase expression of cardioprotective biomarkers associated with the renin-angiotensin and kallikrein-kinin systems. J Cardiovasc Pharmacol. 2018 Dec;72(6):291-5. doi: 10.1097/FJC.0000000000000629, PMID 30422889
Ashish KS, Ajit Kumar S, Mukesh, Manas M. High compliance and persistence with antihypertensive therapy: The esprit study. Clin Drug Investig. 2004;24(11):713-23. doi: 10.2165/00044011-200424110- 00002
Published
How to Cite
Issue
Section
Copyright (c) 2025 Jainishkamleshkumarmodi Jainishkamleshkumarmodi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
